A.M. Vitals: Lilly Profit Beats Analysts’ Expectations (By a Penny)


Published On: January 28th, 2011

Also: the FDA says no to Avodart as a prostate cancer preventive; WellPoint looks to diversify; Berwick renominated.

Read the rest here:
A.M. Vitals: Lilly Profit Beats Analysts’ Expectations (By a Penny)



Loading...


Comments are closed.